1 / 10

How to Solve Melanoma Tumor Heterogeneity

Intratumoral heterogeneity is one of the key reasons that lead to the failure of anticancer therapy and death of patients and is also an important issue that researchers are trying to solve. <br><br><br>Learn more about ADC at https://www.creative-biolabs.com/resource/adc/pdf/com/downloads/HER2-ADC-preparation-and-potency-evaluation-Creative-Biolabs.pdf

bellasmith123
Download Presentation

How to Solve Melanoma Tumor Heterogeneity

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Creative Biolabs How to Solve Melanoma Tumor Heterogeneity https://www.creative-biolabs.com/adc/

  2. Intratumoral heterogeneity is one of the key reasons that lead to the failure of anticancer therapy and death of patients and is also an important issue that researchers are trying to solve. A few days ago, researchers at the Netherlands National Cancer Institute (Netherland Cancer Institute) and Genmab Research showed that the use of anti-drug conjugate (ADC) targeting AXL can kill specific melanoma cells in mice. The triple combination of this therapy with BRAF/MEF inhibitors is likely to improve the efficacy of melanoma patients. Background

  3. An important signaling pathway in melanoma. Mutations in the BRAF gene promote tumor cell proliferation. The BRAF/MEK inhibitor combination therapy developed for this target is the current standard of care and is usually effective for melanoma patients BRAF signaling pathway 1 2

  4. Recent Study The researchers found that a lots of tumor cells that are resistant to BRAF/MEK inhibitors are able to express a highly receptor tyrosine kinase known as AXL on the cell surface. Therefore, the development of AXL-targeted therapeutic approaches has naturally become the goal of their research for a long time.

  5. Working with Genmab, the researchers combined AXL antibodies with the disrupted microtubule drug monomethyl auristatin E to make an ADC. They found that this ADC, called AXL-107-MMAE, as a monotherapy can effectively destroy tumor cells that are highly expressed in AML in melanoma, lung, pancreas, and cervical cancer in a mouse model. And the common denominator of ADC drug' payloads is their extremely high toxicity and low selectivity, which makes them difficult to use as small molecule drugs. These toxins were often studied as chemical drugs but were abandoned because TI was too small and late emerging toxicity. It is broadly divided into two categories. One that targets tubulin and inhibits microtubule mechanics, including maytansinoids and dolastatin. Another type targets a DNA groove, after which the DNA double helix is disrupted, including duocarmycin ADC and calicheamicins. Reserach results

  6. In general, there is a population of tumor cells that highly express AXL and hardly expressing AXL in melanoma, which is also a manifestation of intratumoral heterogeneity. AXL-107-MMAE and BRAF/MEK inhibitors complement each other in melanoma to destroy different types of tumor cells, thereby synergistically achieving the effect of inhibiting tumor growth. Moreover, the researchers found that BRAF/MEK inhibitors can promote the expression of AXL in tumor cells. Therefore, the use of BRAF/MEK inhibitors in combination with AXL-107-MMAE can further enhance the efficacy of AXL-107-MMAE. Reserach results

  7. Conclusions This study shows that AXL-107-MMAE therapy is worthy of being further tested in clinical trials on its potential in treating cancer patients who have never received treatment or have developed resistance to other therapies, whether as a monotherapy or combination therapy. Despite these unidentified factors, the antibody durg conjugates therapy still plays a significant role in the field of cancer treatment around the world and will bring great treating effects for a huge amount of patients who suffering for a variety of diseases. We expect these new results will further advance the development of this therapy and bring new treatment options to these patients as soon as possible.

  8. Established in 2004, Creative Biolabs is highly specialized in advanced antibody biochemistry and engineering, including ADC customs products. With more than a decade of exploration and expansion, our current research and service capacity covers the entire new drug discovery and antibody conjugation service, which ranges from early discovery, pre-clinical evaluations, cGMP manufacturing, dar conjugation to clinical trials. As an international cooperation, Creative Biolabs has established multiple offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with our customers and research partners to develop new medicines for a better, healthier world. Creative Biolabs

  9. Contact Us 45-1 Ramsey Road, Shirley, NY 11967, USA Email: marketing@creative-biolabs.com

  10. Creative Biolabs Thank You https://www.creative-biolabs.com/adc/

More Related